-
Fate Therapeutics (FATE) ASH Abstracts 'Underappreciated' - BMO
-
Fate Therapeutics (FATE) PT Raised to $7 at BMO Capital
-
BMO Positive on Fate Therapeutics (FATE) Following Adaptive NK Cell Therapy-Focused ASH Dinner
-
Fate Therapeutics (FATE) Fast Track Provides Greater FDA Access - BMO Capital
-
BMO Capital Starts Fate Therapeutics (FATE) at Outperform
-
Fate Therapeutics (FATE) Bullish Stance Reiterated at BMO Capital Following Meetings
-
Fate Therapeutics' (FATE) Boston Children Hospital Deal Broadens ProHema Franchise Into Autoimmune Disease, BMO Capital Says
-
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Fate Therapeutics (FATE) Prices 6M Common Offering at $5/Share
-
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
-
Fate Therapeutics (FATE) Announces 6M Common Offering
-
Fate Therapeutics Announces Proposed Public Offering of Common Stock
-
Fate Therapeutics Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 5/6: (DIS) (FATE) (OCLR) (CRAY)
-
BMO Capital Says Juno Deal 'Validates' Fate Therapeutics (FATE) Stem Cell Modulation Platform
-
Fate Therapeutics (FATE) Target Price Lifted at BMO Capital
-
BMO Capital Starts Fate Therapeutics (FATE) at Outperform
-
Fate Therapeutics (FATE) IPO Opens Higher
-
Fate Therapeutics (FATE) IPO Set to Open on NASDAQ
-
Fate Therapeutics (FATE) Files $69M IPO